The Nama Traditional Leaders Association (NTLA) and the Ovaherero Traditional Authority (OTA) have strongly rejected the impending conclusion of the joint declaration ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

AdvisorNet Financial Inc grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 96.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,085 shares of the company ...

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Technical analysis for Intellia Therapeutics Inc. NTLA including support levels resistance levels and stop losses for NTLA ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

NDAQ:NTLA) Shareholders that lost money on Intellia Therapeutics, Inc. (NTLA) should contact Levi & Korsinsky about ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...